Koninklijke Philips NV vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Koninklijke Philips NV trades at $24.24 (market cap $23.52B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.35 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 13.8× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| PHG | VEA | |
|---|---|---|
Market Cap | $23.52B | $323.80B |
Volume | 1,635,069 | 17,001,112 |
Sector | Health | — |
52-Week High | $32.91 | $73.79 |
52-Week Low | $23.81 | $58.90 |
Typical Hold Time | 84 Days | 131 Days |
Enterprise Value | $29.87B | — |
Dividend Yield | 4.17% | — |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.30, up 0.87% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong cash flow generation. Recent news highlights product innovations including new CT systems and AI healthcare advancements, while institutional ownership shows mixed activity.
The outlook remains cautious with analyst consensus at Hold (63.64%) despite positive earnings momentum. Key risks include cybersecurity threats and competitive pressures in health technology. The stock presents a recovery opportunity but requires monitoring of execution risks and market sentiment shifts.
VEA trades at $69.86, down 0.57% with a bearish technical signal (17 sell indicators vs 4 buy). The ETF maintains strong institutional interest with multiple firms increasing positions in Q2 2026. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. The fund provides exposure to developed markets excluding US equities, with established economies like Canada and Japan.
VEA offers cost-efficient international diversification but faces near-term technical headwinds. The fund's low expense ratio and dividend yield provide structural advantages, though current bearish momentum suggests potential for further downside. Key risks include global market volatility and currency fluctuations affecting international holdings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →